Table 3.

Comparison of clinical variables in MM patients with IgE levels of <11.5 IU/mL and >11.5 IU/mL (median)

IgE
< 11.5 IU/mL> 11.5 IU/mLP
N100101
Mean age, y59.5 ± 1.1559.2 ± 1.060.84
Stage, n (%)
    I5 (5)8 (7.9)
    II25 (25)28 (27.7)0.59
    III70 (70)65 (64.4)
Mean Hb level, g/dL10.63 ± 0.25*11.28 ± 0.230.05
Creatinine, n (%)
    <2 mg/dL87 (87)91 (90.1)0.50
    >2 mg/dL13 (13)10 (9.9)
Mean β2M level, mg/dL4.96 ± 0.353.58 ± 0.19§0.01
Albumine, g/dL3.8 ± 0.083.8 ± 0.060.68
Treatment, n (%)
    Conventional only33 (33)35 (34.6)0.80
    SCT67 (67)66 (65.3)
        Autologous6364
        Allogeneic42
        First line6164
        Second line62
Thalidomide, n (%)33 (33)34 (33.6)0.92
  • NOTE: Mean levels are expressed as mean ± SE.

  • * Hb available in 99 patients.

  • Hb available in 98 patients.

  • β2M available in 81 patients.

  • § β2M available in 77 patients.

  • Albumin available in 65 patients.

  • Albumin available in 58 patients.